1 / 37

MANAGEMENT OF ESOPHAGEAL CANCER

Elshami Elamin, MD Medical Oncologist Central Care Cancer Center www.cccancer.com Newton, KS - USA. MANAGEMENT OF ESOPHAGEAL CANCER. ESOPHAGEAL CANCER. Risk factors Alcohol / Tobacco Head / neck cancer High fat, low protein & calories Barrett’s Tylosis

lois-boone
Download Presentation

MANAGEMENT OF ESOPHAGEAL CANCER

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Elshami Elamin, MD Medical Oncologist Central Care Cancer Center www.cccancer.com Newton, KS - USA MANAGEMENT OF ESOPHAGEAL CANCER

  2. ESOPHAGEAL CANCER • Risk factors • Alcohol / Tobacco • Head / neck cancer • High fat, low protein & calories • Barrett’s • Tylosis • Plummer Vinson syndrome (Paterson-Brown-kelly Synd) • Achalasia

  3. Symptoms & Signs • Dysphagia • Wt. Loss • Cough • Pain • Hoarseness • Malig pleural effusion, Ascites • Hypercalcemia

  4. Work-Up H&P EGD CBC, CMP CT chest/abd No Mets: Bronchoscopy *Tumor at or above Carina EUS Laparoscopy (GEJ) PET/CT Locoregional I-III/IVA IVB

  5. INTRODUCTION • Surgery has been the raditional management of patients with localised esophageal cancer • Survival is poor, and many pts develop mets or locoregional recurrence soon after surgery

  6. Treatment modalities • Esophagectomy: • Resectable esophageal cancer: • >5 cm from cricopharyngeus • Cervical and cervicothoracic cancer i.e <5 cm from cricopharyngeus should be treated with definitive chemoradiation. • R.T. • Chemotherapy • BSC

  7. Medically Fit • Resectable (>5cm from cricopharyngeus) • Multidisiplinary Eval • Nutritional Assessment (NGT, J-Tube, PEG not recommended) Locoregional I-III/IVA IVB Salvage Therapy • Inresectable: T4 • Medically unfit

  8. GEJ: Celiac nodal involvement may not exclude combined modality therapy • Resectable stage IVA: • Distal esophageal cancer with resectable celiac node • No involvement of aorta or other organ • No involvement of celiac artery • ReseInvctable T4: • Involvement of • Pericardium • Pleura • Diaphragm

  9. Medically Fit • Resectable disease

  10. Endoscopic mucosal resection OR • Esophagectomy Tis, T1a • Medically Fit • Resectable • Esophagectomy (preferred for noncervical) T1b,N0-1 T1b, N1 T2-4, N0-1,Nx M1a (IVA)

  11. Preop Chemo for adeno of distal Esoph or GEJ (ECF) T1b, N1 T2-4, N0-1,Nx M1a (IVA) Definitive ChemoRT PreopChemoRT RT 50-50.4 Gy

  12. Preop Chemo for adeno of distal Esoph or GEJ See Surgical outcome Esophagectomy Salvage esophagectomy for local residual disease PET-CT/CT *EGD Definitive ChemoRT PreopChemoRT RT 50-50.4 Gy PET-CT/CT *EGD *EGD > 5 wks with biopsy or brushings

  13. NED Esophagectomy (preferred) Observe See Surgical outcome PreopChemoRT RT 50-50.4 Gy • Esophagectomy (preferred) • paliative/ (chemo) PET-CT/CT *EGD Persistent local dis unresectable Mets *EGD > 5 wks with biopsy or brushings

  14. Surgical outcomes Tis, T1, N0: observe adeno T2,N0: observe or chemoRT*ECF if given preop (categ 1) N - T3,N0: chemoRT *ECF if given preop (categ 1) Squamous R0 Observe Adenoprox or mid N+ Observe or chemoRT Adeno distal or GEJ chemoRT *ECF if given preop (categ 1) R1 chemoRT R2 chemoRT or palliative

  15. Medically Unfit • Unresectable dis.

  16. Endoscopic mucosal resection OR • ChemoRT Tis, T1a • Medically unfit • unresectable • ChemoRT • Chemo • RT • BSC • Medically unfit • Chemo is tolerable • Unresectable: T4/IVA • Medically unfit • Chemo is not tolerable Palliative RT BSC

  17. ANY SCEINTIFIC EVIDENCE TO SUPPORT THE USE OF CHEMOTHERAPY/R.T. IN LOCALLY ADVANCED OPERABLE ESOPHAGEAL/GASTRIC CANCER?

  18. LITRETURE REVIEW

  19. ADJUVANT THERAPY • Adj RT, chemo, or chemoRT • Mixed results and disappointing • Because trials were small and lacked statistical power • Adj treatment based on 2 or 3-year survival rates • chemoRT and chemo have similar benefits

  20. NEOADJUVANT THERAPY • Due to sig postop complication rate, focus has turned to neoadj treatment. • Currently, there is no evidence to support the use of neoadj RT alone

  21. Any role for Chemo/RT • <30% of locally advanced Gastric/GEJ adeno could be cure with surgery alone • Previous adj chemo failed to show clinical benefit

  22. INT-0116 (SWOG 9008) Adj Option • Randomized lll Trial: • Resectable adeno of stomach • GEJ (lB-IVA) • 5-FU/LVx5d--> RT+5-FU/LV during first 4d and last 3d of RT --> 2cycles of 5-FU/LVx5d • postop CT/RT improve DFS&OS in R0 (resected locally advanced) • [standard of care] • Macdonald et al; N Engl J Med. 2001 Sep 6;345(10):725-30.

  23. The MAGIC TrialThe Medical Research Council Adjuvant Gastric Infusional Chemotherapy • Operable adeno of the stomach, the lower third of the esophagus, and the GEJ ( 74% of pts had tumors in the stomach) • ECFx3->surg->ECFx3 (250 pts) vs Surgery alone (253 pts): • 5Y survival: 36% vs 23% • Chemo sig. improves resectability, PFS and OS Periop. option • D. Cunningham, et al ; N Engl J Med. 2006 Jul 6;355(1):11-20.

  24. Preoperative Chemotherapy vs Surgery Alone FNLCC ACCORD 07-FFCD 9703, multicenter, randomized trial indicated benefit of preoperative chemotherapy vs surgery alone for resectable adenocarcinoma of stomach and lower esophagus[1] Higher rate of R0 resection (87% vs 74%; P = .04) Higher 5-yr OS (38% vs 24%; P = .021) No increase in postoperative morbidity or mortality Boige V, et al. ASCO 2007; Abstract 4510.

  25. Preoperative Chemotherapy vs Surgery Alone Meta-analysis also demonstrated benefit for preoperative chemotherapy in resectable esophageal cancer[2] 5-yr OS benefit of 4.3% (P = .003) 5-yr DFS benefit of 4.4% (P = .0001) Thirion P, et al. ASCO 2007. Abstract 4512.

  26. CALGB 9781 • Only 56 pt with stage I-III • Preop-chemo/RT vs surgery alone • MS 4.5y vs 1.8y • Trimodality imroves survival

  27. Survival benefits from neoadjuvantchemoradiotherapy orchemotherapy in oesophageal carcinoma(meta-analysis)Val Gebski, Bryan Burmeister, B Mark Smithers, KerwynFoo, John Zalcberg, John Simes, for the Australasian Gastro-Intestinal Trials Group Lancet Oncol 2007; 8: 226–34

  28. Meta-analysis • MEDLINE, Cancerlit, and EMBASE databases from major scientific meetings (1980-2006) • Pts with local operable esophageal ca • 10 randomised trials of neoadjuvant chemoRT vs surgery (n=1209) • SCC = 6, adeno =1, both = 3 • 8 of neoradjuvant chemo vs surgery (n=1724) with comparisons • SCC = 7, both = 2

  29. Meta-analysisFindings • The hazard ratio for all-cause mortality with neoadj chemoRT vr surgery • 0·81 (95% CI 0·70–0·93; p=0·002) • corresponding to a 13% absolute difference in survival at 2 years • 0·84 (0·71–0·99; p=0·04) for SCC • 0·75 (0·59–0·95; p=0·02) for adeno • The hazard ratio for neoadj chemo was 0·90 (0·81–1·00;p=0·05) • 2-year absolute survival benefit of 7% • No sig effect on all-cause mortality of chemo for SCC (hazard ratio 0·88 [0·75–1·03]; p=0·12) • Sig benefit for adeno (0·78 [0·64–0·95]; p=0·014)

  30. NEOADJ CHEMO • For SCC, neoadj chemo did not have a survival benefit • hazard ratio for mortality 0・88 [0・75–1・03] • p = 0・12 • For adeno, neoadj chemo showed sig survival benefit (UK Medical Research Council MRC trial) • hazard ratio for mortality 0・78 [0・64–0・95] • P = 0・014

  31. Long term results of the MRC OEO2 randomized trial of surgery with or without preoperative chemotherapy in resectable esophageal cancer • Conclusions: Long term follow-up confirms that preoperative chemotherapy improves survival in operable esophageal cancer and should be considered as a standard of care. • 2002 (Lancet 2002; 359: 1727-33)

  32. NEOADJUVANTCHEMO/RT • Neoadj chemoRT vs surgery • sign benefit over surgery for both histological types • 0・84 (0・71–0・99); p = 0・04 for SCC • 0・75 (0・59–0・95); p = 0・02 for adeno

  33. Sequential vs Concurrent chemoRT • No survival benefit of sequential chemoRT in SCC • hazard ratio for mortality 0・90 [0・72–1・03]; p=0・18) • similar to SCC treated with neoadj chemo • Concurrent chemoRT had sig benefit for both histological types • hazard ratios 0・76 and 0・75 for SCC and adeno, respectively

  34. Meta-analysisInterpretation • A signifi cant survival benefi t was evident for preoperative chemoradiotherapy and, to a lesser extent, for chemotherapy in patients with adenocarcinoma of the oesophagus.

  35. MDACC study: Salvage Resection for Esophageal Carcinoma: OS • No difference in OS between salvage and planned resection • 5-year survival 46% for salvage vs 42% for planned resection OS 1.0 Planned surgery 0.8 Salvage 0.6 Cumulative Survival Probability 0.4 P = .125 0.2 0.0 60 0 30 50 10 40 20 Months Median follow-up: 24 months Hofstetter WL, et al. GI Cancers Symposium 2009. Abstract 7.

  36. THANKS

More Related